Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.33 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.